Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.79 |
| ▸ | CA2 | P00918 | 2/20 | 0.79 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30738251 | 1.00 | CA1 (0.79) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL21346113 | 0.96 | CA1 (0.73) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL21346179 | 0.96 | CA1 (0.73) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL21346474 | 0.94 | CA1 (0.72) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL2742531 | 0.93 | CA1 (0.78) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL2742529 | 0.93 | CA1 (0.82) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL6382633 | 0.92 | CA1 (0.69) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL146690 | 0.92 | CA1 (0.69) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL4026085 | 0.92 | CA1 (0.69) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL6802359 | 0.92 | ALDH1A1 (0.70) | CA1CA2CA12CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117551094-B | Preparation method of high-optical-purity rotundine | 云南省药物研究所 | 2024-04-05 | — | — | CN | claimed |
| CN-117551094-A | Preparation method of high-optical-purity rotundine | 云南省药物研究所 | 2024-02-13 | — | — | CN | claimed |
| CN-111848512-A | Powder injection pharmaceutical composition prepared from high-purity papaverine hydrochloride | 山东北大高科华泰制药有限公司 | 2020-10-30 | — | — | CN | claimed |
| EP-0054174-B1 | TOPICAL COSMETIC FORMULATIONS FOR THE TREATMENT OF VERY GREASY HAIR AND SEBORRHOEIC SKIN | Henkel Kommanditgesellschaft auf Aktien (DE) | 1986-08-20 | — | — | EP | claimed |
| CN-117551094-B | Preparation method of high-optical-purity rotundine | 云南省药物研究所 | 2024-04-05 | — | — | CN | disclosed |
| CN-117551094-B | Preparation method of high-optical-purity rotundine | 云南省药物研究所 | 2024-04-05 | — | — | CN | disclosed |
| CN-117551094-A | Preparation method of high-optical-purity rotundine | 云南省药物研究所 | 2024-02-13 | — | — | CN | disclosed |
| CN-117551094-A | Preparation method of high-optical-purity rotundine | 云南省药物研究所 | 2024-02-13 | — | — | CN | disclosed |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| CN-111848512-A | Powder injection pharmaceutical composition prepared from high-purity papaverine hydrochloride | 山东北大高科华泰制药有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-8815900-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-08-26 | — | — | US | disclosed |
| US-8815900-B2 | Compounds and compositions for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-08-26 | — | — | US | disclosed |
| US-5681954-A | HAS CALMODULIN INHIBITORY ACTIVITY; USEFUL IN TREATING DISEASES OF THE CIRCULATORY ORGANS OR IN CEREBRAL REGION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | disclosed |
| WO-1997029106-A1 | CORALYNE ANALOGS AS TOPOISOMERASE INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1997-08-14 | — | — | WO | disclosed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | disclosed |
| US-4956389-A | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS WITH N-METHYL-N-BIS(3,4-DIMETHOXYPHENYLETHYL)AMINE | YASON S.R.L. (IT) | 1990-09-11 | — | — | US | disclosed |
| US-4493823-A | USING CARBOXYBENZENE COMPOUND | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-01-15 | — | — | US | disclosed |
| EP-0054174-A2 | Topical cosmetic formulations for the treatment of very greasy hair and seborrhoeic skin | Henkel Kommanditgesellschaft auf Aktien (DE) | 1982-06-23 | — | — | EP | disclosed |
| US-4192877-A | BIS(POLYALKOXYBENZYL)-TETRAHYDROISOQUINOLIUM ALKYL M- OR P- PHENYLENE DIPROPIONATE SALT | MASSACHUSETTS GENERAL HOSPITAL (US) | 1980-03-11 | — | — | US | disclosed |
| US-4126615-A | RANEY NICKEL CATALYST | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | CA1 4218/4885CA2 3697/4885CA12 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.